Sharekhan's research report on Sun Pharma
Sun Pharma continues to remain surrounded by issues, the recent one being a whistle blower case filed with SEBI. Related party structure raises concerns among investors.
Outlook
We downgrade our recommendation to Hold with downward revised PT of Rs. 525.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
